The thai phase III HIV type 1 vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120

AIDS Research and Human Retroviruses

Volumn 28, Issue 11, 2012, Pages 1444-1457

  Karasavvas, Nicos ^a   Billings, Erik ^b   Rao, Mangala ^c   Williams, Constance ^d   Zolla Pazner, Susan ^d,e   Bailer, Robert T ^f   Koup, Richard A ^f   Madnote, Sirinan ^a   Arworn, Duangnapa ^a   Shen, Xiaoying ^g   Tomaras, Georgia D ^g   Currier, Jeffrey R ^b   Jiang, Mike ^h   Magaret, Craig ^h   Andrews, Charla ^b   Gottardo, Raphael ^h   Gilbert, Peter ^h   Cardozo, Timothy J ^d   Rerks Ngarm, Supachai ⁱ   Nitayaphan, Sorachai ^a   Pitisuttithum, Punnee ^j   Kaewkungwal, Jaranit ^k   Paris, Robert ^c,l   Greene, Kelli ^m   Gao, Hongmei ^m   Gurunathan, Sanjay ⁿ   Tartaglia, Jim ⁿ   Sinangil, Faruk ^o   Korber, Bette T ^p   Montefiori, David C ^m   Mascola, John R ^m   Robb, Merlin L ^b   Haynes, Barton F ^g   Ngauy, Viseth ^a   Michael, Nelson L ^c   Kim, Jerome H ^c   De Souza, Mark S ^a   more..

^a ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Veterans Affairs NY Harbor Healthcare System Room 13051 C   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Fred Hutchinson Cancer Research Center   (United States)

ⁱ MINISTRY OF PUBLIC HEALTH   (Thailand)

^j MAHIDOL UNIVERSITY   (Thailand)

^k MAHIDOL UNIVERSITY   (Thailand)

^l WALTER REED ARMY MEDICAL CENTER   (United States)

^m DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁿ SANOFI PASTEUR   (France)

^o Global Solutions for Infectious Diseases   (United States)

^p LOS ALAMOS NATIONAL LABORATORY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO; VALINE;

AMINO ACID SEQUENCE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE; VACCINATION;

AIDS VACCINES; AMINO ACID SEQUENCE; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, T-LYMPHOCYTE; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MALE; MOLECULAR SEQUENCE DATA; PROTEIN ARRAY ANALYSIS;

EID: 84868589536     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0103     Document Type: Article

References (69)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al.: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361(23):2209-2220.
2. Kim JH, Rerks-Ngarm S, Excler JL, and Michael NL: HIV vaccines: Lessons learned and the way forward. Curr Opin HIV AIDS 2010;5(5):428-434.
3. Haynes BF, Liao HX, and Tomaras GD: Is developing an HIV-1 vaccine possible? Curr Opin HIV AIDS 2010;5(5):362-367.
4. Nitayaphan S, Pitisuttithum P, Karnasuta C, et al.: Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J Infect Dis 2004;190(4):702-706.
5. Karnasuta C, Paris RM, Cox JH, et al.: Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine 2005;23(19):2522-2529.
6. Cao H, Kaleebu P, Hom D, et al.: Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canar-ypox vaccine in HIV-seronegative Ugandan volunteers: Results of the HIV Network for Prevention Trials 007 Vaccine Study. J Infect Dis 2003;187(6):887-895.
7. Gupta K, Hudgens M, Corey L, et al.: Safety and immuno-genicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J Acquir Immune Defic Syndr 2002;29(3):254-261.
8. Evans TG, Keefer MC, Weinhold KJ, et al.: A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis 1999;180(2):290-298.
9. Belshe RB, Gorse GJ, Mulligan MJ, et al.: Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. AIDS 1998;12(18):2407-2415.
10. Pitisuttithum P, Gilbert P, Gurwith M, et al.: Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194(12):1661-1671.
11. Flynn NM, Forthal DN, Harro CD, et al.: Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005;191(5):654-665.
12. Gilbert PB, Peterson ML, Follmann D, et al.: Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005;191(5):666-677.
13. Hessell AJ, Poignard P, Hunter M, et al.: Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 2009;15(8):951-954.
14. Shibata R, Igarashi T, Haigwood N, et al.: Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 1999;5(2):204-210.
15. Baba TW, Liska V, Hofmann-Lehmann R, et al.: Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000;6(2):200-206.
16. Mascola JR, Stiegler G, VanCott TC, et al.: Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000;6(2):207-210.
17. Barouch DH, Liu J, Li H, et al.: Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012;482:89-93.
18. Barnett SW, Burke B, Sun Y, et al.: Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope gly-coprotein in MF59 adjuvant. J Virol 2010;84(12):5975-5985.
19. Lambert JS, Mofenson LM, Fletcher CV, et al.: Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group. J Infect Dis 1997;175(2):283-291.
20. Haynes BF, Gilbert PB, McElrath MJ, et al.: Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012;366(14):1275-1286.
21. Montefiori DC, Karnasuta C, Huang Y, et al.: Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis 2012; 206(3):431-441.
22. Chen B, Vogan EM, Gong H, et al.: Structure of an un-liganded simian immunodeficiency virus gp120 core. Nature 2005;433(7028):834-841.
23. Arthos J, Cicala C, Martinelli E, et al.: HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol 2008;9(3):301-309.
24. Cicala C, Martinelli E, McNally JP, et al.: The integrin al-pha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci USA 2009;106(49):20877- 20882.
25. Walker LM, Simek MD, Priddy F, et al.: A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog 2010;6(8).
26. Doores KJ and Burton DR: Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol 2010;84(20):10510- 10521.
27. Hu G, Liu J, Taylor KA, and Roux KH: Structural comparison of HIV-1 envelope spikes with and without the V1/V2 loop. J Virol 2011;85(6):2741-2750.
28. Spurrier B, Sampson JM, Totrov M, et al.: Structural analysis of human and macaque mAbs 2909 and 2.5B: Implications for the configuration of the quaternary neutralizing epitope of HIV-1 gp120. Structure 2011;19(5):691-699.
29. Lynch RM, Shen T, Gnanakaran S, and Derdeyn CA: Appreciating HIV type 1 diversity: Subtype differences in Env. AIDS Res Hum Retroviruses 2009;25(3):237-248.
30. Sagar M, Wu X, Lee S, and Overbaugh J: Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J Virol 2006;80(19):9586-9598.
31. Moore PL, Ranchobe N, Lambson BE, et al.: Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog 2009;5(9): e1000598.
32. O'Rourke SM, Schweighardt B, Phung P, et al.: Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus. J Virol 2010;84(21):11200-11209.
33. Pinter A, Honnen WJ, He Y, et al.: The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J Virol 2004;78(10):5205-5215.
34. Sagar M: HIV-1 transmission biology: Selection and characteristics of infecting viruses. J Infect Dis 2010;202(Suppl 2): S289-2 96.
35. Chohan B, Lang D, Sagar M, et al.: Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J Virol 2005;79(10):6528-6531.
36. Derdeyn CA, Decker JM, Bibollet-Ruche F, et al.: Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 2004;303(5666):2019-2022.
37. Wagner N, Lohler J, Kunkel EJ, et al.: Critical role for beta7 integrins in formation of the gut-associated lymphoid tissue. Nature 1996;382(6589):366- 370.
38. von Andrian UH and Mackay CR: T-cell function and migration. Two sides of the same coin. N Engl J Med 2000; 343(14):1020-1034.
39. Parrish NF, Wilen CB, Banks LB, et al.: Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin alpha4beta7. PLoS Pathog 2012;8(5):e1002686.
40. Walker LM, Phogat SK, Chan-Hui PY, et al.: Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009;326(5950):285-289.
41. Zolla-Pazner S and Cardozo T: Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nat Rev Immunol 2010;10(7):527-535.
42. Changela A, Wu X, Yang Y, et al.: Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1. J Virol 2011;85(6):2524-2535.
43. Moore PL, Gray ES, Sheward D, et al.: Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J Virol 2011;85(7):3128-3141.
44. Gorny MK, Stamatatos L, Volsky B, et al.: Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J Virol 2005;79(8):5232-5237.
45. Honnen WJ, Krachmarov C, Kayman SC, et al.: Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence. J Virol 2007;81(3):1424-1432.
46. Robinson JE, Franco K, Elliott DH, et al.: Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4. J Virol 2010;84(7):3443-3453.
47. McLellan JS, Pancera M, Carrico C, et al.: Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011;480:336-343.
48. Gorny MK, Moore JP, Conley AJ, et al.: Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J Virol 1994;68(12):8312-8320.
49. de Souza MS, Ratto-Kim S, Chuenarom W, et al.: The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol 2012;188(10):5166- 5176.
50. Rolland M, Larsen B, and Edlefsen P: Sequence Analysis of HIV-1 Breakthrough Infections in the RV144 Trial. Presented at AIDS Vaccine 2011, Bangkok, Thailand, September 12-15, 2011. Abstract.
51. Gaschen B, Taylor J, Yusim K, et al.: Diversity considerations in HIV-1 vaccine selection. Science 2002;296(5577):2354-2360.
52. Sandberg M, Eriksson L, Jonsson J, et al.: New chemical descriptors relevant for the design of biologically active peptides. A multivariate characterization of 87 amino acids. J Med Chem 1998;41(14):2481-2491.
53. Droit A, Cheung C, and Gottardo R: rMAT-an R/Bio-conductor package for analyzing ChIP-chip experiments. Bioinformatics 2010;26(5):678-679.
54. Robb ML, Rerks-Ngarm S, Nitayaphan S, et al.: Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: A post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis 2012;12(7):531-537.
55. Haynes BF: Case Control Study of the RV144 Trial for Immune Correlates: The Analysis and Way Forward. Presented at AIDS Vaccine 2011, Bangkok, Thailand, September 12-15, 2011.
56. Liao H-X, Bonsignori M, Alam SM, et al.: HIV-1 Envelope Antibodies Induced by ALVAC-AIDSVAX B/E Vaccine Target a Site of Vaccine Immune Pressure Within the C b Strand of gp120 V1V2. Presented at Keystone Symposia 2012, Keystone, Colorado, March 21-26, 2012. Abstract.
57. Belhadj Jrad B and Bahraoui E: Antigenicity of linear and cyclic peptides mimicking the disulfide loops in HIV-2 envelope glycoprotein: Synthesis, reoxidation and purification. J Pept Res 1998;51(5):370-385.
58. Misumi S, Endo M, Mukai R, et al.: A novel cyclic peptide immunization strategy for preventing HIV-1/AIDS infection and progression. J Biol Chem 2003;278(34):32335-32343.
59. Bogdanowich-Knipp SJ, Jois DS, and Siahaan TJ: The effect of conformation on the solution stability of linear vs. cyclic RGD peptides. J Pept Res 1999;53(5):523-529.
60. Mezo G, Majer Z, Vass E, et al.: Conformational study of linear and cyclic peptides corresponding to the 276-284 epitope region of HSV gD-1. Biophys Chem 2003;103(1):51-65.
61. Hoogerhout P, Donders EM, van Gaans-van den Brink JA, et al.: Conjugates of synthetic cyclic peptides elicit bactericidal antibodies against a conformational epitope on a class 1 outer membrane protein of Neisseria meningitidis. Infect Immun 1995;63(9):3473-3478.
62. Beddows S, Lister S, Cheingsong R, et al.: Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals. J Virol 1999;73(2):1740-1745.
63. Abrahams MR, Anderson JA, Giorgi EE, et al.: Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-Poisson distribution of transmitted variants. J Virol 2009;83(8):3556-3567.
64. Sagar M, Laeyendecker O, Lee S, et al.: Selection of HIV variants with signature genotypic characteristics during heterosexual transmission. J Infect Dis 2009;199(4):580-589.
65. Rong R, Bibollet-Ruche F, Mulenga J, et al.: Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. J Virol 2007;81(3):1350-1359.
66. Nawaz F, Cicala C, Van Ryk D, et al.: The genotype of early-transmitting HIV gp120s promotes alphabeta-reactivity, revealing alphabetaCD4+ T cells as key targets in mucosal transmission. PLoS Pathog 2011;7(2):e1001301.
67. Cicala C, Arthos J, and Fauci AS: HIV-1 envelope, integrins and co-receptor use in mucosal transmission of HIV. J Transl Med 2010;9(Suppl 1):S2.
68. Israel ZR, Gorny MK, Palmer C, et al.: Prevalence of a V2 epitope in clade B primary isolates and its recognition by sera from HIV-1-infected individuals. AIDS 1997;11(1):128-130.
69. Kowalski M, Potz J, Basiripour L, et al.: Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science 1987;237(4820):1351-1355.